Ryan Dougherty

Mr. Ryan Dougherty

Georgetown University
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
RDRyan Dougherty
Ryan Dougherty
SVsahar vakili
sahar vakili
AFAlexandra M. Ferraro
Alexandra M. Ferraro
LKLi-Wei Kuo
Li-Wei Kuo
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
CD133, known as prominin1, is a penta-span transmembrane glycoprotein presumably a cancer stem cell marker for carcinomas, glioblastomas, and melanomas. We showed that CD133(+) ‘melanoma-initiating cells’ are associated with chemoresistance, contributing to poor patient outcome. The current study investigates the role(s) of CD133 in invasion and metastasis. Magnetic-activated cell sorting of a melanoma cell line (BAKP) followed by transwell invasion assays revealed that CD133(+) cells are significantly more invasive than CD133(−) cells. Conditional reprogramming of BAKP CD133(+) cells maintained stable CD133 overexpression (BAK-R), and induced cancer stem cell markers, melanosphere formation, and chemoresistance to kinase inhibitors. BAK-R cells showed upregulated CD133 expression, and consequently were more invasive and metastatic than BAK-P cells in transwell and zebrafish assays. CD133 knockdown by siRNA or CRISPR-Cas9 (BAK-R-T3) in BAK-R cells reduced invasion and levels of matrix metalloproteinases MMP2/MMP9. BAK-R-SC cells, but not BAK-R-T3, were metastatic in zebrafish. While CD133 knockdown by siRNA or CRISPR-Cas9 in BAK-P cells attenuated invasion and diminished MMP2/MMP9 levels, doxycycline-induced CD133 expression in BAK-P cells enhanced invasion and MMP2/MMP9 concentrations. CD133 may therefore play an essential role in invasion and metastasis via upregulation of MMP2/MMP9, leading to tumor progression, and represents an attractive target for intervention in melanoma.

16 July 2019 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
Anirudh GaurAnirudh Gaur
Anirudh Gaur
HZHengbo Zhou
Hengbo Zhou
MAMaryam AbdusSamad
Maryam AbdusSamad
QQQing Qin
Qing Qin
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
FDA-approved kinase inhibitors are now used for melanoma, including combinations of the MEK inhibitor trametinib, and BRAF inhibitor dabrafenib for BRAFV600 mutations. NRAS-mutated cell lines are also sensitive to MEK inhibitionin vitro, and NRAS-mutated tumors have also shown partial response to MEK inhibitors. However, melanoma still has high recurrence rates due to subpopulations, sometimes described as “melanoma initiating cells,” resistant to treatment. Since CD133 is a putative cancer stem cell marker for different cancers, associated with decreased survival, we examined resistance of patient-derived CD133(+) and CD133(-) melanoma cells to MAPK inhibitors. Human melanoma cells were exposed to increasing concentrations of trametinib and/or dabrafenib, either before or after separation into CD133(+) and CD133(-) subpopulations. In parental CD133-mixed lines, the percentages of CD133(+) cells increased significantly (p<0.05) after high-dose drug treatment. Presorted CD133(+) cells also exhibited significantly greater (p<0.05) IC50s for single and combination MAPKI treatment. siRNA knockdown revealed a causal relationship between CD133 and drug resistance. Microarray and qRT-PCR analyses revealed that ten of 18 ABC transporter genes were significantly (P<0.05) upregulated in the CD133(+) subpopulation, while inhibition of ABC activity increased sensitivity, suggesting a mechanism for increased drug resistance of CD133(+) cells.

Verified
Journal Article
Open access
PDF file
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
YHYogameenakshi Haribabu
Yogameenakshi Haribabu
SVsahar vakili
sahar vakili
LKLi-Wei Kuo
Li-Wei Kuo
HCHelen Havens Clark
Helen Havens Clark
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
Malignant melanoma is a lethal skin cancer containing melanoma-initiating cells (MIC) implicated in tumorigenesis, invasion, and drug resistance, and is characterized by the elevated expression of stem cell markers, including CD133. The siRNA knockdown of CD133 enhances apoptosis induced by the MEK inhibitor trametinib in melanoma cells. This study investigates the underlying mechanisms of CD133’s anti-apoptotic activity in patient-derived BAKP and POT cells, harboring difficult-to-treat NRASQ61K and NRASQ61R drivers, after CRISPR-Cas9 CD133 knockout or Dox-inducible expression of CD133. MACS-sorted CD133(+) BAKP cells were conditionally reprogrammed to derive BAKR cells with sustained CD133 expression and MIC features. Compared to BAKP, CD133(+) BAKR exhibit increased cell survival and reduced apoptosis in response to trametinib or the chemotherapeutic dacarbazine (DTIC). CRISPR-Cas9-mediated CD133 knockout in BAKR cells (BAKR-KO) re-sensitized cells to trametinib. CD133 knockout in BAKP and POT cells increased trametinib-induced apoptosis by reducing anti-apoptotic BCL-xL, p-AKT, and p-BAD and increasing pro-apoptotic BAX. Conversely, Dox-induced CD133 expression diminished apoptosis in both trametinib-treated cell lines, coincident with elevated p-AKT, p-BAD, BCL-2, and BCL-xL and decreased activation of BAX and caspases-3 and -9. AKT1/2 siRNA knockdown or inhibition of BCL-2 family members with navitoclax (ABT-263) in BAKP-KO cells further enhanced caspase-mediated apoptotic PARP cleavage. CD133 may therefore activate a survival pathway where (1) increased AKT phosphorylation and activation induces (2) BAD phosphorylation and inactivation, (3) decreases BAX activation, and (4) reduces caspases-3 and -9 activity and caspase-mediated PARP cleavage, leading to apoptosis suppression and drug resistance in melanoma. Targeting nodes of the CD133, AKT, or BCL-2 survival pathways with trametinib highlights the potential for combination therapies for NRAS-mutant melanoma stem cells for the development of more effective treatments for patients with high-risk melanoma.

21 September 2019 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
BCBonnie C Carney
Bonnie C Carney
RDRyan Dougherty
Ryan Dougherty
LMLauren T Moffatt
Lauren T Moffatt
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
JSJeffrey W Shupp
Jeffrey W Shupp
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
Burn injuries frequently result in hypertrophic scars, specifically when excision and grafting are delayed due to limited resources or patient complications. In patient populations with dark baseline pigmentation, one symptom of hypertrophic scar that often occurs is dyspigmentation. The mechanism behind dyspigmentation has not been explored, and, as such, prevention and treatment strategies for this morbidity are lacking. The mechanism by which cells make pigment is controlled at the apex of the pathway by pro-opiomelanocortin (POMC), which is cleaved to its products alpha-melanocyte stimulating hormone (α-MSH) and adrenocorticotropin hormone (ACTH). α-MSH and ACTH secreted by keratinocytes binds to melanocortin 1 receptor (MC1R), expressed on melanocytes, to initiate melanogenesis. POMC protein expression is upregulated in hyperpigmented scar compared to hypopigmented scar by an unknown mechanism in a Duroc pig model of HTS. POMC RNA levels, as well as the POMC gene promoter methylation status was investigated as a possible mechanism. DNA was isolated from biopsies obtained from distinct areas of hyper- or hypo-pigmented scar and normal skin. DNA was bisulfite-converted, and amplified using two sets of primers to observe methylation patterns in two different CpG islands near the POMC promoter. Amplicons were then sequenced and methylation patterns were evaluated. POMC gene expression was significantly downregulated in hypopigmented scar compared to normal skin, consistent with previously reported protein expression levels. There were significant changes in methylation of the POMC promoter, however, none that would account for the development of hyper- or hypo-pigmentation. Future work will focus on other areas of POMC transcriptional regulation.

1 January 2025 in Case Reports in Anesthesiology
Verified
Journal Article
Open access
RNRei Ndoni
Rei Ndoni
ASAariya Srinivasan
Aariya Srinivasan
RDRyan Dougherty
Ryan Dougherty
CNColin Nahrstedt
Colin Nahrstedt
JLJia Liu
Jia Liu
SASABRY AYAD
SABRY AYAD
This case report details the successful use of awake fiberoptic intubation in a 28‐year‐old pregnant patient at 21 weeks gestation, who presented for diagnostic mediastinoscopy with biopsy secondary to a large anterior mediastinal mass suspected to be lymphoma. MRI displayed encasement of the superior mediastinal vasculature and 13.0 cm × 7.6 cm coalescence in the anterior mediastinum. Given the size of the mass and potential for airway and vascular complications, awake fiberoptic intubation was chosen to ensure safety for both mother and fetus. The case underscores the efficacy of awake fiberoptic intubation in complex airway management scenarios in pregnant patients, highlighting the importance of a multidisciplinary approach to optimize patient care and outcomes.